A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy. The anticipated time of study treatment is until disease progression, and the target sample size is 500+ individuals.
Non-Squamous Non-Small Cell Lung Cancer
DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Placebo|DRUG: bevacizumab [Avastin]|DRUG: bevacizumab [Avastin]
Progression-free survival, Event driven
Efficacy: Duration of overall survival, time to treatment failure, response rate, and duration of response., Event driven|Safety:AEs, laboratory tests, SAEs, coagulation parameters, Throughout study
This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy. The anticipated time of study treatment is until disease progression, and the target sample size is 500+ individuals.